Please ensure Javascript is enabled for purposes of website accessibility

Why Clovis Oncology Tumbled 13.5% Today

By Todd Campbell - Jul 31, 2017 at 4:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

News of a collaboration with Bristol-Myers Squibb dashed some of investor's hopes that Clovis Oncology could get acquired.

What happened

After disclosing that it's entered into a pact with Bristol-Myers Squibb (BMY 1.59%) on its cancer-fighting drug Rubraca, shares in Clovis Oncology (CLVS -0.73%) lost 13.5% of their value Monday.

So what

While teaming up with biopharma giant Bristol-Myers Squibb would normally be viewed as a good thing, investors had sent shares soaring ahead of today's announcement in hopes of an acquisition. Thus, they walked away today disappointed.

A man holds his head in his hands in front of a chart showing a declining share price.

IMAGE SOURCE: GETTY IMAGES.

Although a deal was what investors wanted to see, Bristol-Myers Squibb's willingness to partner up with Clovis Oncology on Rubraca could someday expand Rubraca's peak sales potential.

Bristol-Myers Squibb will supply its PD-1 cancer-fighting drug Opdivo so that the two companies can evaluate whether using Opdivo and Rubraca together can improve outcomes for patients with various tumor types. Phase 3 trials will study the two-drug combination in first-line maintenance treatment for ovarian and advanced triple-negative breast cancer. The company will also conduct phase 2 studies to see if using Opdivos and Rubraca together can tackle metastatic castration-resistant prostate cancer.

Now what

Clovis Oncology will head up the ovarian cancer study, while Bristol-Myers Squibb will run the breast cancer and prostate cancer studies. It will be a bit before we know if this mash-up works, but it's a very intriguing one-two punch.

PD-1 drugs, including Opdivo, keep cancer cells from hijacking proteins that allow them to escape detection by the immune system. Meanwhile, Rubraca is a PARP-inhibitor that keeps cancer cells from using proteins to repair damage that's caused by chemotherapy, or other cancer treatments.

Opdivo has quickly become one of the top-selling cancer drugs available, generating over $1.1 billion in sales last quarter alone. Rubraca is relatively new to the market, but it and competing PARP inhibitors are generating nine figures in annual sales, and growing. 

It's anyone guess if Clovis Oncology and Bristol-Myers Squibb's drug trials will succeed, and there doesn't appear to be any money changing hands between these companies. Therefore, it's understandable that M&A-hungry investors sold this company's news today.

Nevertheless, long-term investors ought to be encouraged that companies like Bristol-Myers Squibb continue to focus attention on PARP inhibitor combination therapies. After all, if these multi-drug studies pan out, the PARP drug market could end up being worth billions of dollars in annual sales someday.

Todd Campbell has no position in any stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clovis Oncology, Inc. Stock Quote
Clovis Oncology, Inc.
CLVS
$1.36 (-0.73%) $0.01
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$75.33 (1.59%) $1.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.